RUSSELL M. WILDER, Ph.D., M.D., F.A.C.P.
This content is PDF only. Please click on the PDF icon to access.
A year ago, at the meeting of the American College of Physicians, Dr. Joslin expressed the opinion that Hagedorn by effectively retarding the action of insulin with protamines had opened a new era in the treatment of diabetes. During the past year hundreds of physicians have had the opportunity to use protamine insulin in the treatment of diabetes, and I am informed that their verdict is almost unanimously favorable. In February of this year an improved modification of Hagedorn's preparation was placed on the market. It already had received the official endorsement of the Insulin Committee in Toronto and that
WILDER RM. CLINICAL INVESTIGATIONS OF INSULINS WITH PROLONGED ACTIVITY*. Ann Intern Med. 1937;11:13–30. doi: https://doi.org/10.7326/0003-4819-11-1-13
Download citation file:
Published: Ann Intern Med. 1937;11(1):13-30.
Cardiology, Coronary Risk Factors, Diabetes, Endocrine and Metabolism.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use